BioPharmSignal logoBioPharmSignal

Biotech News

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Rallybio (RLYB)RallybioFinancing

Combined company to operate as Candid Therapeutics, advancing a leading portfolio of T-cell engager therapeutics for autoimmune diseases Concurrent significantly oversubscribed and upsized financing of over $505 million committed by a syndicate of leading healthcare institutional investors and

Related news

RLYBRallybio2026-06-01 12:00 EST

Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement

BDRXBiodexa Pharmaceuticals2026-06-30 12:00 EST

Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants

PTCTPTC Therapeutics, Inc.2026-06-16 03:14 EST

PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes

PTCTPTC Therapeutics, Inc.2026-06-15 11:00 EST

PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes

PHVSPharvaris2026-05-11 20:15 EST

Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares

BIIBBiogen2026-08-24 12:04 EST

LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease

EDITEditas Medicine2026-05-26 13:05 EST

Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering

PHVSPharvaris2026-05-08 10:00 EST

Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares

BIIBBiogen2026-09-01 11:30 EST

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

EDITEditas Medicine2026-05-26 10:15 EST

Editas Medicine Announces Proposed Public Offering

View all latest news

Rallybio

Rallybio is a rare-disease biotechnology company focused on complement and immune-mediated disorders. Its pipeline aims at high-unmet-need conditions where targeted biology matters.

Recent company news

RLYBRallybio2026-06-01 12:00 EST

Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement

RLYBRallybio2026-03-02 13:00 EST

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

RLYBRallybio2026-02-17 13:00 EST

Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

RLYBRallybio2026-02-03 21:05 EST

Rallybio Announces Reverse Stock Split of Common Stock

RLYBRallybio2025-11-06 13:00 EST

Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Stock data

Close
16.93 USD
Market cap
94.13M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States